|
|
 |
|
Viewing report
|
|
|
|
Drug Discovery Outsourcing Market in China
Frost & Sullivan, Sep 2010, Pages: 67
This Market Engineering research service has been developed to address the dynamics of Drug Discovery in China. The market covers four main area, that is gene sequencing, target ID, target validation and lead discovery. This research service presents the key findings of drug discovery outsourcing in china. It provides insight and forecast of market size. This research service also discusses market trends, market drivers, market restraints and Chinese government initiatives. The study completes with a section on recommendation and decision support tables.
This Frost & Sullivan research service titled Drug Discovery Outsourcing Market in China provides an overview of the market and examines the drivers and restraints for growth as well as government initiatives. It also analyzes demand and geographical trends. In addition, it provides an in-depth analysis of the competitive situation. The study concludes with a section on the key strategic recommendations and future outlook.
Market Overview
Cost Benefits and Considerable Scientific Expertise Provide China a Position of Advantage for Drug Discovery Outsourcing
With fast-paced advancements in genomics, combinatorial chemistry, and high-throughput screening, China has emerged as a major location to which drug discovery is being outsourced. The Chinese drug discovery outsourcing market reached $315.0 million in 2009 and is expected to grow at a compound annual growth rate (CAGR) of 23.0 percent from 2009 to 2016. China has the advantages of scientific expertise and comprehensive infrastructure, which are critical for drug discovery activities. Apart from India, China is also regarded as a lucrative market, which will help pharmaceutical firms improve drug discovery at a reasonable cost. Rising overhead cost in the United States and European countries has led companies to opt for outsourcing of drug discovery to low-cost countries such as China and India. “Expired patents and rise in diseases are expected to fuel the growth of the Chinese drug discovery market,” notes the analyst of this research service. “China offers a large talent pool in the field of pharmaceutical research and development, including an increasing number of western-educated graduates or researchers having international working experience.” The Chinese Government has been providing strong incentives to nurture the domestic pharmaceutical and biopharmaceutical industries. The R&D sector in China has largely benefited from these initiatives, which include tax relief, direct funding opportunities, and development of numerous technology/biotechnology parks, especially in Shanghai.
Although the prospects for the market look upbeat, there are some challenges clouding its landscape. With economic reforms and the expected inflation in China, labor and raw material costs are witnessing an uptrend. The impact is not likely to be felt immediately. However, in the near future, cost is bound to witness a hike. Companies are expected to be scouting around for alternative locations that can offer more cost-effective options. Apart from this, data security and intellectual property (IP) protection in China have caused some angst for large international pharmaceutical and biotechnology companies. The Government is stepping up efforts to address IP issues; however, it is likely to take a while before these problems are ironed out.
Pharmaceutical companies have displayed a preference for a single outsourcing firm instead of multiple providers for a project. This helps eliminate dealings with numerous outsourcing companies and enables optimal leverage of the knowledge obtained during the early stages of R&D process within the same organization. As the environment encourages companies to conduct vigorous R&D in this space, they must strive to move up the value chain and attain global standards at par with large western pharmaceutical companies.. “Multinational companies as well as local sponsors perceive overall service quality as the uppermost priority in the selection of an outsourcing partner,” says the analyst. “In addition, factors such as price, ability to recruit trial participants, speed of project turnaround, as well as reputation of the drug discovery firm are also the major decisive factors.” Companies that have capitalized on the available resources for drug discovery are also keen to broaden their business horizons and build up sales in the Chinese market. Thus, new opportunities are unfolding for the development of drugs especially relevant for the Chinese market.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Pharmaceutical Analytical Services Outsourcing in India: Cost Savings, Product Quality and Shorter Delivery Times are Key Drivers
The Drug Discovery Outsourcing Market
Southeast Asian Pharmaceuticals Industry: Generic Drug Market
Drug Discovery in India and China - Gaining Momentum with Increasing Pressure on Cost Cutting
Emerging Pharmaceutical Market in China - Forecast to Become The World’s Third-Largest Pharmaceutical Market By 2013
The Future of Contract Research Outsourcing - Market Forecasts to 2015, Geographical Landscape and Competitive Benchmarking
Overview of the European Drug Discovery Market
Future Outlook of China Preclinical and Toxicology Outsourcing
The New Trends of Global Pharmaceutical Outsourcing: New Developments in Strategy, Market, Service and Technology
Lead Generation Strategies and Technologies in Drug Development - Emerging Techniques Such as Antisense Technology Will Allow Innovators to Minimize Costs
|
|
|
|
